vs
Side-by-side financial comparison of Douglas Elliman Inc. (DOUG) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $245.4M, roughly 1.1× Douglas Elliman Inc.). Douglas Elliman Inc. runs the higher net margin — 27.9% vs -45.7%, a 73.6% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 0.9%). Douglas Elliman Inc. produced more free cash flow last quarter ($-14.7M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 10.7%).
Douglas Elliman Inc. is a leading U.S.-based residential real estate brokerage firm. It offers luxury property sales, rentals, property management, and advisory solutions, serving high-net-worth clients across key metro markets including New York, California, Florida, and Texas.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
DOUG vs GH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $245.4M | $281.3M |
| Net Profit | $68.6M | $-128.5M |
| Gross Margin | — | 64.6% |
| Operating Margin | 27.3% | -43.0% |
| Net Margin | 27.9% | -45.7% |
| Revenue YoY | 0.9% | 39.4% |
| Net Profit YoY | 1243.4% | -15.8% |
| EPS (diluted) | $0.80 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $245.4M | $281.3M | ||
| Q3 25 | $262.8M | $265.2M | ||
| Q2 25 | $271.4M | $232.1M | ||
| Q1 25 | $253.4M | $203.5M | ||
| Q4 24 | $243.3M | $201.8M | ||
| Q3 24 | $266.3M | $191.5M | ||
| Q2 24 | $285.8M | $177.2M | ||
| Q1 24 | $200.2M | $168.5M |
| Q4 25 | $68.6M | $-128.5M | ||
| Q3 25 | $-24.7M | $-92.7M | ||
| Q2 25 | $-22.7M | $-99.9M | ||
| Q1 25 | $-6.0M | $-95.2M | ||
| Q4 24 | $-6.0M | $-111.0M | ||
| Q3 24 | $-27.2M | $-107.8M | ||
| Q2 24 | $-1.7M | $-102.6M | ||
| Q1 24 | $-41.5M | $-115.0M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 59.1% | ||
| Q1 24 | — | 61.2% |
| Q4 25 | 27.3% | -43.0% | ||
| Q3 25 | -4.1% | -37.3% | ||
| Q2 25 | -2.0% | -45.9% | ||
| Q1 25 | -2.1% | -54.6% | ||
| Q4 24 | -6.7% | -62.4% | ||
| Q3 24 | -2.8% | -61.3% | ||
| Q2 24 | -1.3% | -56.8% | ||
| Q1 24 | -20.7% | -59.2% |
| Q4 25 | 27.9% | -45.7% | ||
| Q3 25 | -9.4% | -35.0% | ||
| Q2 25 | -8.4% | -43.0% | ||
| Q1 25 | -2.4% | -46.8% | ||
| Q4 24 | -2.5% | -55.0% | ||
| Q3 24 | -10.2% | -56.3% | ||
| Q2 24 | -0.6% | -57.9% | ||
| Q1 24 | -20.7% | -68.2% |
| Q4 25 | $0.80 | $-1.01 | ||
| Q3 25 | $-0.29 | $-0.74 | ||
| Q2 25 | $-0.27 | $-0.80 | ||
| Q1 25 | $-0.07 | $-0.77 | ||
| Q4 24 | $-0.06 | $-0.90 | ||
| Q3 24 | $-0.33 | $-0.88 | ||
| Q2 24 | $-0.02 | $-0.84 | ||
| Q1 24 | $-0.50 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $115.5M | $378.2M |
| Total DebtLower is stronger | — | $1.5B |
| Stockholders' EquityBook value | $183.9M | $-99.3M |
| Total Assets | $444.4M | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $115.5M | $378.2M | ||
| Q3 25 | $143.0M | $580.0M | ||
| Q2 25 | $136.3M | $629.1M | ||
| Q1 25 | $136.8M | $698.6M | ||
| Q4 24 | $145.5M | $525.5M | ||
| Q3 24 | $151.4M | $585.0M | ||
| Q2 24 | $92.9M | $933.7M | ||
| Q1 24 | $91.5M | $1.0B |
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $183.9M | $-99.3M | ||
| Q3 25 | $115.1M | $-354.5M | ||
| Q2 25 | $137.6M | $-305.5M | ||
| Q1 25 | $158.2M | $-250.8M | ||
| Q4 24 | $162.2M | $-139.6M | ||
| Q3 24 | $173.6M | $-60.1M | ||
| Q2 24 | $196.9M | $-1.6M | ||
| Q1 24 | $195.1M | $68.3M |
| Q4 25 | $444.4M | $2.0B | ||
| Q3 25 | $480.6M | $1.3B | ||
| Q2 25 | $489.0M | $1.3B | ||
| Q1 25 | $493.9M | $1.3B | ||
| Q4 24 | $493.9M | $1.5B | ||
| Q3 24 | $502.7M | $1.5B | ||
| Q2 24 | $463.9M | $1.6B | ||
| Q1 24 | $461.1M | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.4M | $-26.4M |
| Free Cash FlowOCF − Capex | $-14.7M | $-54.2M |
| FCF MarginFCF / Revenue | -6.0% | -19.3% |
| Capex IntensityCapex / Revenue | 0.1% | 9.9% |
| Cash ConversionOCF / Net Profit | -0.21× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-17.2M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-14.4M | $-26.4M | ||
| Q3 25 | $5.5M | $-35.4M | ||
| Q2 25 | $642.0K | $-60.3M | ||
| Q1 25 | $-5.6M | $-62.7M | ||
| Q4 24 | $-9.0M | $-64.5M | ||
| Q3 24 | $9.0M | $-51.1M | ||
| Q2 24 | $1.3M | $-94.0M | ||
| Q1 24 | $-27.3M | $-30.3M |
| Q4 25 | $-14.7M | $-54.2M | ||
| Q3 25 | $4.7M | $-45.8M | ||
| Q2 25 | $-575.0K | $-65.9M | ||
| Q1 25 | $-6.7M | $-67.1M | ||
| Q4 24 | $-10.2M | $-83.4M | ||
| Q3 24 | $7.7M | $-55.3M | ||
| Q2 24 | $432.0K | $-99.1M | ||
| Q1 24 | $-29.4M | $-37.2M |
| Q4 25 | -6.0% | -19.3% | ||
| Q3 25 | 1.8% | -17.3% | ||
| Q2 25 | -0.2% | -28.4% | ||
| Q1 25 | -2.6% | -33.0% | ||
| Q4 24 | -4.2% | -41.3% | ||
| Q3 24 | 2.9% | -28.9% | ||
| Q2 24 | 0.2% | -55.9% | ||
| Q1 24 | -14.7% | -22.1% |
| Q4 25 | 0.1% | 9.9% | ||
| Q3 25 | 0.3% | 3.9% | ||
| Q2 25 | 0.4% | 2.4% | ||
| Q1 25 | 0.4% | 2.2% | ||
| Q4 24 | 0.5% | 9.4% | ||
| Q3 24 | 0.5% | 2.2% | ||
| Q2 24 | 0.3% | 2.9% | ||
| Q1 24 | 1.0% | 4.1% |
| Q4 25 | -0.21× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOUG
| Commissions And Other Brokerage Income | $240.3M | 98% |
| Property Management Income | $2.8M | 1% |
| Property Management | $2.2M | 1% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
